It may therefore interfere with methylation- dependent metabolism and indicate poor flow through the methionine cycle
FDA Commissioner Marty Makary stated publicly: "We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms." The regulatory environment around GLP-1-adjacent products is tightening
The Acetyl component of this improves the ability to cross the blood brain barrier, improve dopamine and by improving dopamine it improves other areas such as cognition, learning, attention, memory, desire, pleasure, punishment, reward, motivation, sleep, mood, behaviour, and voluntary movement
First, approximately 1 in 4 patients had discontinued treatment at 1 year after treatment initiation, and almost half had discontinued at 3 years, with these findings being largely similar for GLP-1 receptor agonists and SGLT2 inhibitors
Immunology of endometriosis